Inpefa (Sotagliflozin) Patent Expiration, LOE Window & CMS Spending

Inpefa (Sotagliflozin) by Lexicon: FDA Orange Book core substance LOE 2030-10-07, 0 AB generics, $6.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLexicon
FDA Application & PathwayN216203 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-10-07
Last Listed Patent or Exclusivity Date2030-10-07
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$6.7M
2024 Medicare Part D Spend$5.9M
2024 Medicaid Spend$872K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel